Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
Retrieved on:
Wednesday, January 10, 2024
Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, CDAD, Development, Woman, Hydrogen chloride, Hypersensitivity, Patient, OGN, Frustration, Thermoregulation, Gynaecology, History, Bacterial vaginosis, Clostridioides, Environment, Recurrence, Research and development, BV, Bacteria, Clindamycin, Lincomycin, Infection, American College
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription to treat bacterial vaginosis (BV).
Key Points:
- Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription to treat bacterial vaginosis (BV).
- Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.
- If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued.
- Information about XACIATO, and the eVoucher instant savings coupon for eligible patients, can be found at XACIATO.com .